# A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

> **NCT03375697** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 72 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** JNJ-63733657
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03375697
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-22
- **Primary completion:** 2019-12-16
- **Final completion:** 2019-12-16
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375697, "A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03375697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*